Table 2.
Progression-free survival results for patient characteristics and biomarkers
| N | No. Events |
Median Years |
HR | 95 % CI for HR |
HR p-value |
|
|---|---|---|---|---|---|---|
| Race | ||||||
| Non-White | 9 | 9 | 1.77 | |||
| White | 57 | 57 | 1.93 | 1.20 | (0.57, 2.54) | 0.64 |
| Gleason score | ||||||
| 5–7 | 13 | 13 | 3.59 | |||
| 8–10 | 51 | 51 | 1.60 | 1.77 | (0.94, 3.34) | 0.08 |
| Performance Status | ||||||
| 0 | 31 | 31 | 1.97 | |||
| 1–2 | 35 | 35 | 1.70 | 1.20 | (0.74, 1.96) | 0.46 |
| Metastatic Volume | ||||||
| Low | 31 | 31 | 3.53 | |||
| High | 35 | 35 | 1.27 | 2.93 | (1.70, 5.05) | <0.001 |
| Treatment | ||||||
| ADT | 34 | 34 | 1.60 | |||
| ADT + Chemo | 31 | 31 | 2.29 | 0.99 | (0.60, 1.61) | 0.95 |
| Diabetes | ||||||
| No | 62 | 62 | 1.93 | |||
| Yes | 4 | 4 | 0.92 | 2.28 | (0.80, 6.45) | 0.12 |
| Age | 66 | 66 | 1.77 | 0.99 | (0.96, 1.02) | 0.67 |
| PSA (ln) | 66 | 66 | 1.77 | 1.00 | (0.99, 1.01) | 0.65 |
| Insulin (ln) | 66 | 66 | 1.77 | 0.81 | (0.67, 0.98) | 0.03 |
| RANK (ln) | 66 | 66 | 1.77 | 0.82 | (0.60, 1.12) | 0.22 |
| IGFBP3 (ln) | 66 | 66 | 1.77 | 0.89 | (0.52, 1.51) | 0.66 |
| IGFBP1 (ln) | 66 | 66 | 1.77 | 1.05 | (0.87, 1.27) | 0.59 |
| IGF I | 66 | 66 | 1.77 | 0.85 | (0.42, 1.74) | 0.66 |
| IGF II | 66 | 66 | 1.77 | 0.80 | (0.27, 2.42) | 0.70 |
| HGF (ln) | 66 | 66 | 1.77 | 1.63 | (1.06, 2.51) | 0.03 |
| OPN | 66 | 66 | 1.77 | 1.56 | (1.13, 2.15) | 0.01 |
| C-peptide (ln) | 66 | 66 | 1.77 | 0.62 | (0.39, 1.00) | 0.05 |
| PD1 (ln) | 66 | 66 | 1.77 | 0.82 | (0.53, 1.25) | 0.35 |
| IL6 (ln) | 66 | 66 | 1.77 | 1.26 | (0.91, 1.75) | 0.17 |
| OPG (ln) | 66 | 66 | 1.77 | 0.97 | (0.84, 1.11) | 0.63 |
PSA prostate specific antigen, RANK Receptor Activator of Nuclear Factor k B, IGFBP insulin-like growth factor binding protein, IGF insulin-like growth factor, HGF hepatocyte growth factor, OPN osteopontin, PD1 Programmed cell death protein 1, IL6 interleukin-6, OPG Osteoprotegerin
For continuous measures, the HR is based on a one unit difference in the measurement